Fusarium infection in hematopoietic stem cell transplant recipients

• Main Author: Nucci, M.
• Publication Date: 2004
• Other Authors: Marr, K. A., Queiroz-Telles, F., Martins, C. A., Trabasso, P., Costa, S., Voltarelli, J. C., Colombo, Arnaldo Lopes [UNIFESP], Imhof, A., Pasquini, R., Maiolino, A., Souza, C. A., Anaissie, E.
• Format: Article
• Language: eng
• Source: Repositório Institucional da UNIFESP
• Download full: http://repositorio.unifesp.br/handle/11600/27717; http://dx.doi.org/10.1086/383319

To characterize the epidemiology and prognostic factors of invasive fusariosis in hematopoietic stem cell transplant (HSCT) recipients, the records of HSCT recipients from 9 hospitals (7 in Brazil and 2 in the United States) were retrospectively reviewed. Sixty-one cases were identified: 54 in allogeneic HSCT recipients and 7 in autologous HSCT recipients. the incidence of fusariosis among allogeneic HSCT recipients varied between a range of 4.21 - 5.0 cases per 1000 in human leukocyte antigen (HLA) - matched related transplant recipients to 20.19 cases per 1000 in HLA-mismatched transplant recipients. the median time period between transplantation and diagnosis of fusariosis was 48 days. Among allogeneic HSCT recipients, a trimodal distribution was observed: a first peak before engraftment, a second peak at a median of 62 days after transplantation, and a third peak >1 year after transplantation. the actuarial survival was 13% ( median, 13 days). Persistent neutropenia was the single prognostic factor for death identified by multivariate analysis.